- Lobbying
- tiber AND creek AND health AND strategies
Lobbying Arrangements Results for 'Tiber Creek Health Strategies'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Issues affecting the pharmaceutical industry. |
Peck Madigan Jones (on behalf of Acadia Pharmaceuticals, Inc.)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169). |
Tiber Creek Group (on behalf of EMD Serono, Inc.)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169). Issues related to the HHS Notice of Benefit and Payment Pa... |
Tiber Creek Group (on behalf of Bristol Myers Squibb)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to the development of a new cancer therapy. |
Ickes and Enright Group (on behalf of Northwest Biotherapeutics)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to opioid abuse |
Peck Madigan Jones (on behalf of Prevent Opioid Abuse)
|
Tiber Creek Health Strategies, Inc. | |||
Details General background on tax reform, including corporate tax reform. |
Peck, Madigan, Jones & Stewart (On behalf of Semiconductor Industry Association)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169). |
Eli Lilly and Company
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to Medicare Advantage and Medicaid Managed Care |
Comprehensive Health Management, Inc.
|
Tiber Creek Health Strategies, Inc. | |||
Details Work related to a specific patent issue affecting Daiichi Sankyo. |
Tiber Creek Health Strategies, Inc. (On behalf of Daiichi Sankyo, Inc.)
|
Peck, Madigan, Jones & Stewart, Inc. | |||
Details Issues affecting the pharmaceutical industry; issues related to trade. |
Peck Madigan Jones (on behalf of BeiGene USA, Inc.)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169). |
Tiber Creek Group (on behalf of Merck & Co., Inc)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to the Prescription Drug Pricing Reduction Act, HR 1865 - Consolidated Appropriations Act (PL 116-94) Medicare Coverage and Reimbursement for Transformative Therapies. |
Peck Madigan Jones (on behalf of Celgene Corporation)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to FDA oversight of CBD. Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169). |
Tiber Creek Group (obo Jazz Pharmaceuticals)
|
Tiber Creek Health Strategies, Inc. | |||
Details HR 913 - Clinical Treatment Act, drug pricing issues |
Peck Madigan Jones (on behalf of American Society of Clinical Oncology)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to the development of gene therapies |
Peck Madigan Jones (on behalf of Roivant Sciences, Inc.)
|
Tiber Creek Health Strategies, Inc. | |||
Details H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act |
Peck Madigan Jones (on behalf of Association for Clinical Oncology)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to the development of broad-spectrum antivirals. H.R. 1960/S. 1034, National Defense Authorization Act for Fiscal Year 2014. |
Bay Bridge Strategies, Inc. (on behalf of BioCryst Pharmaceuticals)
|
Tiber Creek Health Strategies, Inc. | |||
Details H.R. 6800 the Health and Economic Recovery Omnibus Emergency Solutions Act |
Peck Madigan Jones (on behalf of Legacy Community Health Services)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to implementation of the 21st Century Cures Act (PL: 114-255) and its impact on access to home infusion services. Issues related to implementation of the Bipartisan Budget Act of 201... |
Peck Madigan Jones (on behalf of BioScrip)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to Medicaid funding for the territories |
Peck Madigan Jones (on behalf of InnovaCare, Inc.)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to H.R. 3440/S. 1615 DREAM Act of 2017 and issues related to immigration reform |
Peck Madigan Jones (On behalf of FWD.us)
|
Tiber Creek Health Strategies, Inc. | |||
Details H.R. 9, Innovation Act. S. 1137, the PATENT Act. |
Peck Madigan Jones (On behalf of Micron Technology, Inc.)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to multi-cancer early detection screening; H.R. 2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act. |
GRAIL, LLC
|
Tiber Creek Health Strategies, Inc. | |||
Details Work related to a specific patent issue affecting Daiichi Sankyo. |
Daiichi Sankyo, Inc.
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169). Issues related to sickle cell treatment. |
Tiber Creek Group (On behalf of Vertex Pharmaceuticals)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169). Issues related to the HHS Notice of Benefit and Payment Pa... |
Genentech, Inc.
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476 - Maintaining Investments in New Innovation Act. Is... |
Novartis
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to Medicare Advantage, Medicare Part D and Medicaid Managed Care payment and policy issues, including quality measurement and prescription drug reforms Issues related to the Affordab... |
Tiber Creek Health Strategies, Inc. (obo Comprehensive Health Management, Inc.)
|
Peck Madigan Jones | |||
Details issues related to coverage and reimbursement of pharmaceuticals. Issues related to Medicare, Medicaid. Implementation of Public Law No: 111-148, the Patient Protection and Affordable Care Act. Issu... |
Peck Madigan Jones (On behalf of AbbVie Inc.)
|
Tiber Creek Health Strategies, Inc. | |||
Details Reforms to Medicare Part B. Issues relating to the impact of the biotech industry. Reforms to Medicare Part D. Proposed Medicare and Medicaid cuts. Reforms to Medicare Part B. |
Peck Madigan Jones (On behalf of BIO)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to the Medicare Advantage program. Healthcare delivery system reforms. |
Peck Madigan Jones (on behalf of CAPG)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169). Issues related to the 340b program. |
Pharmaceutical Research and Manufacturers of America (PhRMA)
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part B Pricing Re... |
Tiber Creek Health Strategies, Inc. (On behalf of Genentech, Inc.)
|
Tiber Creek Group | |||
Details Issues related to Medicare reimbursement. |
Fresenius Medical Care North America
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to drug pricing and reimbursement for prescription drugs, Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169). Issues relating to drug pricing; Issue... |
Tiber Creek Health Strategies, Inc. (on behalf of Eli Lilly and Company)
|
Tiber Creek Group | |||
Details Issue related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022. (PL 117-169). |
Amgen, Inc.
|
Tiber Creek Health Strategies, Inc. | |||
Details Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476 - Maintaining Investments in New Innovation Act. Is... |
Tiber Creek Health Strategies, Inc. (On behalf of Novartis)
|
Tiber Creek Group |